title: Tazarotene foam, 0.1%, for the treatment of acne.
abstract: BACKGROUND
  Acne is a common skin condition of the pilosebaceous units that affects the young and old, ranges from moderate to severe and can be treated with an array of options. Topical retinoids are the initial treatment for acne due to their ability to treat comedones, the starting point of acne.
  
  
  METHODS
  Tazarotene is a topical retinoid available as a cream, gel and foam. Tazarotene 0.1% foam was FDA approved in 2012 for the treatment of acne in patients ages ≥12 and is the first foam topical retinoid on the market. Phase I and III trials support the efficacy and safety of tazarotene foam for acne.
  
  
  CONCLUSIONS
  The foam vehicles may increase compliance and satisfaction in some patients and as retinoids are commonly first line acne treatments, this new topical retinoid foam may be a useful option for some acne patients.
authors.affiliation: a Dermatology Research Fellow, Center for Dermatology Research , Department of Dermatology, Wake Forest School of Medicine , Winston-Salem , NC 27157-1071 , USA.
authors.forename: Jaclyn A
authors.initials: JA
authors.lastname: Smith
authors.affiliation: b Dermatology Resident, Center for Dermatology Research , Department of Dermatology, Wake Forest School of Medicine , Winston-Salem , NC 27157-1071 , USA.
authors.forename: Swetha
authors.initials: S
authors.lastname: Narahari
authors.affiliation: c Dermatology Research Fellow, Center for Dermatology Research , Department of Dermatology, Wake Forest School of Medicine , Winston-Salem , NC 27157-1071 , USA.
authors.forename: Dane
authors.initials: D
authors.lastname: Hill
authors.affiliation: d Professor of Dermatology, Center for Dermatology Research , Department of Dermatology, Wake Forest School of Medicine , Winston-Salem , NC 27157-1071 , USA.
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy* / Q000473:pathology; D000279:Administration, Cutaneous; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D055118:Medication Adherence; D009539:Nicotinic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D017060:Patient Satisfaction; D012176:Retinoids
chemical_list: D003879:Dermatologic Agents; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids
keywords: adherence; efficacy; retinoid; topical